Michel Vounatsos, Biogen CEO (Dina Rudick/The Boston Globe via Getty Images)
Biogen loses another bid to revive Tecfidera patent as generic keeps eating into blockbuster sales
When Biogen lost its appeal to revive a key patent for Tecfidera last November, the big biotech filed for a rehearing in a last-ditch effort to restore its crumbling blockbuster multiple sclerosis franchise.
Four months later, the appeals court has rejected its request.
The setback leaves the Supreme Court as Biogen’s final resort if it still wants to block Viatris — formerly Mylan — from marketing a Tecfidera generic, which has and is expected to seriously eat into Tecfidera sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
